QuidelOrtho Corporation (QDEL) Q2 2025 Earnings Call Transcript

QuidelOrtho reported Q2 2025 revenue of $614 million, growing 1% ex-COVID and Donor Screening, driven by strong performance in its Labs (+5%) and Immunohematology (+3%) segments. The company significantly improved profitability, with adjusted EBITDA rising 19% to $107 million and adjusted diluted EPS reaching $0.12, reflecting a 330 basis point expansion in adjusted EBITDA margin to 17% due to effective cost structure actions. Despite lowering full-year COVID revenue guidance to $70M-$100M, QuidelOrtho reiterated its overall 2025 financial outlook, citing offsets from reduced tariff headwinds ($20M-$25M) and savings from the Savanna platform discontinuation. Strategically, the company announced its intent to acquire LEX Diagnostics to bolster its molecular testing portfolio and anticipates mid-single-digit growth in China, leveraging its differentiated clinical chemistry technology.

Analysis

QuidelOrtho's second-quarter 2025 results highlight a successful push for profitability through operational discipline, effectively counteracting modest top-line performance in a seasonally weak period. The company reported total revenue of $614 million, with the core business growing 1% year-over-year, excluding COVID-19 and the winding-down Donor Screening segment. The most significant development was on the margin front, where adjusted EBITDA margin expanded by 330 basis points to 17%, and adjusted diluted EPS grew 271% to $0.12. This was a direct result of cost control measures, including a 9% reduction in non-GAAP operating expenses. While the foundational Labs and Immunohematology businesses delivered consistent growth of 5% and 3% respectively, the company lowered its full-year COVID revenue guidance by $40 million to a new range of $70-$100 million due to lower disease severity trends. Despite this reduction, QuidelOrtho reiterated its full-year guidance for both revenue and adjusted EBITDA. This confidence stems from offsetting factors: a reduced tariff headwind estimate (now $20-$25 million), cost savings from the discontinuation of the Savanna molecular platform, and a neutral FX outlook. Strategically, the company's future in the high-growth molecular space is now pivoted entirely to its intended acquisition of LEX Diagnostics, whose rapid Velo platform is positioned as the key growth driver following a $150 million non-cash charge to exit Savanna.

Key Decisions for Investors

• Investors should prioritize monitoring the execution of cost-saving initiatives, such as the Raritan site consolidation and procurement efficiencies, as these are the primary drivers for achieving the reaffirmed full-year EBITDA guidance despite a lower COVID revenue forecast.
• The FDA clearance and subsequent commercial ramp-up of the LEX Diagnostics Velo platform is now the most critical catalyst for the company's long-term growth; its progress or delay will significantly impact the stock's outlook.
• Consider the relative stability of the China business, guided to mid-single-digit growth, as a potential advantage over peers, but continue to watch for any changes in volume-based procurement or reimbursement policies that could alter this outlook.
• Given the reaffirmed guidance and significant leverage ratio of 4.2x net debt to adjusted EBITDA, progress on the planned Q3 debt refinancing and consistent free cash flow generation in the second half of the year are crucial metrics to track.